Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone augmentation of clozapine

R H McCarthy1, K G Terkelsen

  • 1Cornell University Medical College, New York Hospital-Westchester Division, New York, USA.

Pharmacopsychiatry
|March 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

PharmacoEconomics·1995
Same author

Seizures following smoking cessation in a clozapine responder.

Pharmacopsychiatry·1994
Same author

Esophageal dysfunction in two patients after clozapine treatment.

Journal of clinical psychopharmacology·1994
Same author

Development of clinical methods for utilization review in psychiatric day treatment.

Journal of mental health administration·1994
Same author

Clozapine reduces essential tremor independent of its antipsychotic effect: a case report.

Journal of clinical psychopharmacology·1994
Same author

Home visits in the era of cost containment: comments on Reding, Raphelson and Montgomery's paper.

Community mental health journal·1994
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
Same journal

High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.

Pharmacopsychiatry·2026
See all related articles

Clozapine augmentation with risperidone shows promise for treatment-resistant schizophrenia. This combination may enhance symptom control when clozapine alone is insufficient.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Clozapine is effective for treatment-refractory schizophrenia but often requires augmentation.
  • Common augmentation agents include neuroleptics, mood stabilizers, antidepressants, benzodiazepines, and lithium.

Observation:

  • Classical neuroleptics are frequently added to clozapine, often at antipsychotic doses.
  • Risperidone's efficacy profile suggests it could be a suitable augmentation agent for clozapine.
  • No prior reports exist on the concurrent use of risperidone and clozapine.

Findings:

  • This study presents two cases of successful clozapine augmentation using risperidone.
  • The combined use demonstrated enhanced therapeutic effects.

Implications:

Related Experiment Videos

  • Concurrent use of risperidone and clozapine may be a viable strategy for managing treatment-resistant schizophrenia.
  • Further research is warranted to explore this augmentation approach in larger studies.